Active, not recruitingPhase 4NCT01606488

Effects of Brain Beta-Amyloid on Postoperative Cognition

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Marek Brzezinski, MD, PhD
University of California, San Francisco
Intervention
Florbetapir F 18 (18F-AV-45)(drug)
Enrollment
66 target
Eligibility
65 years · All sexes
Timeline
20122026

Study locations (1)

Collaborators

Alzheimer's Drug Discovery Foundation · Avid Radiopharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01606488 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials